治疗肾性贫血新药 vadadustat.pdf

治疗肾性贫血新药_vadadustat中国新药与临床杂志
Chinese Journal of New Drugs and Clinical Remedies
ISSN 1007-7669,CN 31-17，用于治疗患有 CKD 引起的贫血的成年患者。临床试
验表明，vadadustat 对 CKD 透析和非透析贫血患者的疗效显著，不良反应少。
[中图分类号] R556；R973 [文献标志码] A

A new drug in treatment of renal anemia：vadadustat
DANG Min1, ZHANG Liu-quan2
(1. Jiangsu Wuzhong Suzhou Pharmaceutical Development Co., Ltd, Nanjing Jiangsu 210009,
China; 2. Jiangsu Jinglixin Pharmaceutical Technology Co., Ltd, Nanjing Jiangsu 211198, China)
[KEY WORDS] vadadustat; anemia; renal insufficiency, chronic；hypoxia inducible factor-prolyl
hydroxylase inhibitor
[ABSTRACT] Chronic kidney disease (CKD) is a long-term progressive disease. Anemia is one
of the typical symptoms of advanced CKD. Erythropoiesis-stimulating agents (ESAs) are the
mainstay of renal anemia management but cardiovascular safety concerns have limited their use.
Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) can promote erythrocytogeny
through various actions and correct anemia effectively. Vadadustat, an oral HIF-PHI developed by
Akebia Therapeutics, Inc., was approv